Results 151 to 160 of about 1,408,273 (290)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

The Human Factor H-related Protein 4 (FHR-4) [PDF]

open access: yesJournal of Biological Chemistry, 1997
Christine Skerka   +8 more
openaire   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen   +14 more
wiley   +1 more source

Differentiation of the mononuclear phagocyte system during mouse embryogenesis:the role of transcription factor PU.1 [PDF]

open access: yes, 1999
During mouse embryogenesis, macrophage-like cells arise first in the yolk sac and are produced subsequently in the liver. The onset of liver hematopoiesis is associated with the transition from primitive to definitive erythrocyte production.
Lichanska, A M   +7 more
core  

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

Human Factor H-related Protein 5 (FHR-5) [PDF]

open access: yesJournal of Biological Chemistry, 2001
Jennifer L. McRae   +6 more
openaire   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Genetic Epidemiology of Age-Related Macular Degeneration (AMD): The Role of the Complement Component 2 (C2) and Complement Factor B (CFB) Genes in Determining AMD Subphenotypes [PDF]

open access: yes, 2009
Age-related macular degeneration (AMD) is the most common cause of irreversible blindness in people over the age of 50 in the developed world. Inflammation has a central role in the pathobiology of AMD; complement pathway dysfunction is thought to induce
Longville, Brooke Allison Cattell
core   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. [PDF]

open access: yesKidney Int, 2017
Medjeral-Thomas NR   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy